DOI: https://doi.org/10.36347/sjmcr.2026.v14i05.098

Pages: 1271-1274

Paclitaxel (PTX) and/or cisplatin (CDDP), as important cytotoxic anticancer agents, are widely used to treat various solid tumors. Both may cause moderate or severe neurotoxicity, but ocular neurotoxicity is also occasionally reported. We report a case of a 78-year-old female patient being treated for metastatic right breast cancer involving the bone and lung. She received second-line chemotherapy consisting of weekly paclitaxel. After the fourth cycle, the patient reported blindness in the left eye and blurred vision in the right eye. Brain MRI did not reveal any lesions in the cerebral parenchyma other than bony lesions of the skull vault. An ophthalmological examination was performed and was normal. The patient was treated with glucocorticoids (methylprednisolone), calcium channel blockers (flunarizine), vasodilators, and neurotrophic agents over the following 2 weeks, but her vision did not improve in the 6 months following chemotherapy, and she had a very poor quality of life.